Featured Firms
Presented by BigVoodoo
Brand-name drug makers have a lock on biologics, a group of lucrative, protein-based drugs. But the clock is ticking on many of their patents -- estimated to be worth $10 billion -- and generic manufacturers are eager to jump into the market. The pressure is on federal regulators and Congress to decide whether the generic companies have the know-how to safely replicate biologics, or whether the drugs are best left in the hands of brand-name makers.
July 14, 2004 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Presented by BigVoodoo
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Consulting Magazine recognizes leaders in technology across three categories Leadership, Client Service and Innovation.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS